Jun 2, 2026 08:01AM
Jun 2, 2026 08:00AM
May 14, 2026 08:03AM
May 14, 2026 08:00AM
Mar 18, 2026 08:00AM
Feb 17, 2026 08:02AM
Feb 17, 2026 08:00AM Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Nov 13, 2025 08:00AM
Nov 10, 2025 08:01AM
Nov 10, 2025 08:00AM
Oct 28, 2025 08:01AM
Oct 28, 2025 08:00AM
Oct 23, 2025 04:45PM
Oct 14, 2025 08:04AM FDA accepts Cingulate's drug application for ADHD treatment CTx-1301
Oct 14, 2025 08:00AM
Sep 17, 2025 08:45AM
Sep 17, 2025 08:45AM
Aug 19, 2025 08:45AM
Aug 15, 2025 09:02AM
Aug 15, 2025 09:00AM
Aug 6, 2025 08:45AM Cingulate submits FDA application for ADHD drug CTx-1301
Aug 6, 2025 08:45AM
Jul 29, 2025 08:01AM
Jul 29, 2025 08:00AM
Jul 9, 2025 08:03AM
Jul 9, 2025 08:00AM
May 20, 2025 08:03AM
May 20, 2025 08:00AM Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD
May 14, 2025 08:04AM
May 14, 2025 08:00AM
May 8, 2025 04:30PM
Apr 29, 2025 08:00AM
Apr 3, 2025 08:06AM
Apr 3, 2025 08:00AM
Mar 26, 2025 05:00PM Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
Mar 4, 2025 09:02AM
Mar 4, 2025 09:00AM
Jan 7, 2025 07:30AM
Dec 23, 2024 07:30AM
Nov 7, 2024 07:30AM
Sep 12, 2024 08:30AM
Aug 15, 2024 07:45AM Cingulate Inc (CING) Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD
Aug 15, 2024 07:45AM
Aug 13, 2024 07:45AM
Jun 25, 2024 09:20AM
Jun 25, 2024 09:20AM
May 21, 2024 09:00AM
May 8, 2024 07:00AM
Apr 1, 2024 08:00AM Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
Mar 6, 2024 06:45AM

322,950 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All